KPC Pharmaceuticals Inc
SSE:600422

Watchlist Manager
KPC Pharmaceuticals Inc Logo
KPC Pharmaceuticals Inc
SSE:600422
Watchlist
Price: 17.03 CNY -1.73% Market Closed
Market Cap: 12.9B CNY
Have any thoughts about
KPC Pharmaceuticals Inc?
Write Note

Net Margin
KPC Pharmaceuticals Inc

5.9%
Current
5%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.9%
=
Net Income
446.1m
/
Revenue
7.5B

Net Margin Across Competitors

Country CN
Market Cap 12.9B CNY
Net Margin
6%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 729.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.6T DKK
Net Margin
35%
Country US
Market Cap 347.8B USD
Net Margin
17%
Country US
Market Cap 248.3B USD
Net Margin
19%
Country CH
Market Cap 197.2B CHF
Net Margin
20%
Country UK
Market Cap 159B GBP
Net Margin
13%
Country CH
Market Cap 169.7B CHF
Net Margin
35%
Country US
Market Cap 149.4B USD
Net Margin
7%
No Stocks Found

KPC Pharmaceuticals Inc
Glance View

Market Cap
12.9B CNY
Industry
Pharmaceuticals

KPC Pharmaceuticals Inc., founded in 1951, has cultivated a strong presence in the pharmaceutical industry, rooted in the rich herbal traditions of China. With its headquarters strategically located in Yunnan, a region renowned for its vast biodiversity, KPC leverages this unique advantage by integrating indigenous herbal knowledge into modern pharmaceuticals. The company has carved a niche for itself primarily through the production and distribution of traditional Chinese medicine. This approach not only honors the cultural heritage of its origins but also allows the company to capitalize on a growing global demand for alternative and complementary medical treatments. The blend of traditional herbal medicine and cutting-edge pharmaceutical practices forms the backbone of its business model, enabling KPC to sustain substantial revenue through both local and international markets. Diversification is a cornerstone of KPC Pharmaceuticals' strategy. Beyond its traditional medicines, the company has aggressively pursued research and development in the biopharmaceutical sector. This move has expanded its product offerings to include chemical drugs, biotechnology, and over-the-counter products, broadening their appeal to a more extensive clientele. The continuous investment in R&D has led to the development of innovative treatments for ailments such as cardiovascular diseases, cancer, and other chronic illnesses. Additionally, KPC's robust sales network encompasses hospitals, pharmacies, and other healthcare institutions, ensuring widespread distribution and accessibility of its products. Through this diversified portfolio and strong distribution channels, KPC Pharmaceuticals continues to thrive by meeting the evolving needs of the healthcare industry while maintaining its commitment to quality and efficiency.

Intrinsic Value
24.27 CNY
Undervaluation 30%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
5.9%
=
Net Income
446.1m
/
Revenue
7.5B
What is the Net Margin of KPC Pharmaceuticals Inc?

Based on KPC Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 5.9%.